CRNA platform advances drive up to 60x gene expression and NOK 620M funding
CRNA said its circVec technology achieved up to 60x gene expression in vivo. The company also raised NOK 620 million, securing funding through 2030, and expanded R&D plus 23 collaborations including major pharma.
Major advances in circVec technology drove up to 60x gene expression in vivo, and next-generation designs are targeting a 200x improvement. The company said NOK 620 million was raised, securing funding through 2030 and supporting expanded R&D and 23 collaborations, including with top pharma.